Drug Profile
Zandelisib - MEI Pharma/Kyowa Kirin
Alternative Names: ACC 524; ME-401; PW 143; PWT 143Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pathway Therapeutics
- Developer BeiGene; Kyowa Kirin; MEI Pharma
- Class Amines; Antineoplastics; Benzimidazoles; Inorganic sulfur compounds; Morpholines; Piperidines; Small molecules; Triazines
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
Most Recent Events
- 08 Jun 2023 Updated efficacy and adverse events data from the phase II MIRAGE trial in B-cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 05 May 2023 MEI Pharma terminates a phase I trial in Chronic lymphocytic leukaemia and Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA and Switzerland (PO) due to discontinuation of zandelisib program (NCT02914938)
- 05 May 2023 MEI Pharma terminates a phase I trial in Chronic lymphocytic leukaemia and Follicular lymphoma (Monotherapy, Second-line therapy or greater) in USA and Switzerland (PO) due to discontinuation of zandelisib program (NCT02914938)